One of the main events that occurs in ischemic stroke is cell death. Necrotic cell death is a well-regulated and orchestrated event, also known as programmed cell death or "necroptosis". It is characterized by cell membrane disruption mediated by phosphorylated mixed lineage kinase-like protein (MLKL). Necroptosis can be triggered by a variety of external stimuli and is regulated through caspase-independent pathways. Various studies have shown that necroptosis-related pathways are activated in stroke and play a crucial role in the pathogenesis of stroke. In addition, necroptosis may be of research interest as a potential target for stroke treatment.
Fig. 1. A simplified scheme of necroptotic pathway with inhibitors shown to be protective in in vitro and in vivo models of ischemic brain stroke. (Hribljan et al., 2019)
Ace Therapeutics is a leading company in the field of stroke research, providing comprehensive analysis services to help clients study necroptosis signaling pathways in stroke. Our team of highly skilled experts uses state-of-the-art technology to elucidate the mechanisms of necroptosis in ischemic stroke and develop therapeutic strategies targeting necroptosis for stroke.
Ace Therapeutics provides advanced bioinformatics tools and resources to analyze large-scale genomic data generated from stroke models. Through data integration, differential expression analysis, pathway enrichment analysis, and network analysis, we can identify key molecules and signaling pathways associated with necroptosis in stroke.
We provide in vitro models of ischemic stroke to analyze the effect of inhibiting necroptosis in neurons and astrocytes, as well as the effect of neural stem cell transplantation after stroke on the expression of necroptosis markers.
Ace Therapeutics can help clients to comprehensively investigate the activation mechanism of the necroptosis pathway and its effect on neuronal damage in different stroke animal models. We can use Western blotting, immunohistochemistry, and gene knockdown to deeply analyze the formation of RIP1/RIP3 complex, the activation of downstream effector molecules, and the regulation of neuroprotection.
We offer high-throughput small molecule screening services to identify potential inhibitors or modulators of necroptosis in stroke. Utilizing our extensive compound library and expertise in assay development, we can assess the ability of a large number of compounds to target specific components of the necroptosis signaling pathway.
Ace Therapeutics is at the forefront of necroptosis research, focusing on its critical role in stroke. Leveraging our expertise, state-of-the-art facilities, and a collaborative approach, we offer comprehensive research services to help clients identify therapeutic targets for stroke. Our commitment is to provide clients with valuable data that advances their research objectives and supports their therapeutic development efforts. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.